RXRX — Recursion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.70bn
- $74.68m
Brief: Recursion Pharmaceuticals Inc First Patient Has Been Dosed In Its Phase 2 Clinical Trial Of Rec-3964
U.S. STOCKS ON THE MOVE-Dyne Therapeutics, Maxeon Solar, chip stocks
U.S. STOCKS ON THE MOVE-Walgreens, Copper miners, Simon Property
Recursion falls on mixed mid-stage study data for rare disorder drug
Recursion's blood vessel disorder drug meets main goal in mid-stage study (updated)
Recursion's blood vessel disorder drug meets main goal in mid-stage study
Recursion Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Deals of the day-Mergers and acquisitions
Brief: Recursion Pharmaceuticals Q2 Net Income USD -97.54 Million
Biotech firm Recursion to buy smaller peer Exscientia for $688 million
Recursion Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview
Recursion Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Equity Residential, Goldman Sachs, Marsh & Mclennan
U.S. STOCKS ON THE MOVE-Tempus AI, AeroVironment, Gold miners
U.S. STOCKS ON THE MOVE-Verona Pharma, McCormick, gold miners
U.S. STOCKS ON THE MOVE-Elanco Animal Health, Levi Strauss, SM Energy
U.S. STOCKS ON THE MOVE-International Paper, U.S. Bancorp, Micron Technology
Recursion Pharma slides on deep-discounted $200 mln stock offering
Brief: Recursion Announces Pricing Of $200 Million Public Offering Of Class A Common Stock